Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) stock declines while market improves: Some information for investors
In the latest close session, CRISPR Therapeutics AG (CRSP) was down 8.7% at $55.52. The stock fell short of the S&P 500, ...
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...
CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. CRISPR Therapeutics (NASDAQ: ...
CRISPR Therapeutics analysis: long-term upside despite volatility. Track Casgevy ramp, pipeline milestones & cash runway.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results